SecBot SecBot
Biotech Drug Report Generated Oct 31, 2026

ABBV-295

ABBV·AbbVie Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 2
Time to market
At least 4-6 years. Phase 2 primary completion is estimated March 2028, followed by Phase 3 trials and regulatory filing, putting potential approval in the 2030-2032 timeframe if all goes well.
Why 3/10
No hard binary catalyst is scheduled within the next ~12 months. The Phase 2 dose-finding trial (NCT07752979) has an estimated primary completion of March 2028, and there is no PDUFA or pivotal readout on the horizon. ABBV-295 is an early-stage program at a mega-cap company, making it a very small part of AbbVie's overall value.
Actionable Insight NEUTRAL

The next catalyst is the Phase 2 topline readout, estimated around March 2028. For a mega-cap like AbbVie, even a strong Phase 2 result would be a modest share-price driver. Watch for any interim data presentations at medical conferences in 2027 and for Gubra milestone announcements tied to Phase 2 progress.

Price Chart

Loading chart...

Executive Summary

ABBV-295 is an investigational long-acting amylin analog being developed by AbbVie (NYSE: ABBV) for obesity, licensed from Danish biotech Gubra in March 2025 for $350M upfront and up to $1.875B in milestones. Phase 1 data showed 7.8%-9.8% weight loss at 12 weeks with an 11-12 day half-life, supporting once-weekly or less frequent dosing. A Phase 2 dose-finding trial (NCT07752979) began recruiting in August 2026 with an estimated primary completion of March 2028. The drug is early-stage and represents a very small part of AbbVie's massive pipeline, with no near-term binary catalyst.

How It Works

ABBV-295 is a synthetic, long-acting version of amylin, a natural hormone released by the pancreas after meals that signals the brain to feel full and suppress appetite. It activates amylin and calcitonin receptors, working through a different pathway than popular GLP-1 weight-loss drugs like Ozempic and Wegovy.

Trial Status

Phase 1 completed with positive topline results announced March 9, 2026, and detailed data presented at EASD on September 30, 2026. Phase 2 dose-finding study (NCT07752979) began August 2026, is actively recruiting approximately 360 participants across 63 sites in 2 countries, with a 32-week primary endpoint and estimated primary completion in February/March 2028.

The Two-Sided Case

▲ Bull Case6
Phase 1 data showed 7.8%-9.8% weight loss at 12 weeks on once-weekly dosing, competitive with early-stage GLP-1 data, with a favorable tolerability profile.
ABBV-295 targets amylin receptors, a non-incretin mechanism distinct from GLP-1/GIP agonists, potentially enabling combination therapy and differentiation.
The 11-12 day half-life supports flexible dosing (weekly, every-other-week, or monthly), a potential convenience advantage.
AbbVie's massive commercial infrastructure and experience with Humira/Skyrizi could be leveraged for a successful obesity launch.
Gubra triggered a $50M milestone payment when Phase 2 started, indicating confidence in the program.
Analyst consensus on ABBV is Buy (32 Buy/Strong Buy vs 7 Hold, 0 Sell), with several firms raising price targets in recent months.
▼ Bear Case5
ABBV-295 is a Phase 2 asset at a mega-cap pharma (AbbVie ~$295B market cap), so even a successful readout will have a modest impact on the stock.
The obesity market is intensely competitive, dominated by Novo Nordisk's Wegovy/Ozempic (GLP-1) and Eli Lilly's Zepbound/Mounjaro (GIP/GLP-1). Amylin analogs are an unproven mechanism at scale.
Phase 1 data was mostly in male participants (88.3%), raising questions about generalizability to the broader obesity population.
The drug is years from potential approval (Phase 2 primary completion estimated March 2028, then Phase 3), with no guarantee of success in larger trials.
AbbVie paid $350M upfront with up to $1.875B in milestones, a large bet on an unvalidated mechanism.

Upcoming Catalysts

  • Phase 2 topline readout estimated March 2028 (primary completion of primary endpoint)
  • Potential interim data presentations at medical conferences in 2027 conferences
  • Gubra milestone milestone achievement announcements tied to Phase 2 progress

Source Filing

The SecBot filing or press-release report that triggered this drug report:

AbbVie Inc. 8-K ABBV ·Originating report

Sources · 9

Hover a chip for the title
1 news.abbvie.com2 news.abbvie.com3 news.abbvie.com4 clinicaltrials.gov5 gubra.dk6 fiercebiotech.com7 biospace.com8 investors.abbvie.com9 spzco.com